Commenting on future plans, Mr David Picard, CEO, Moleac, says, "Our main focus will be to increase revenues and extend geographic footage. We will also expand our clinical trial scope to dementia and cognitive impairment, by including centers in Western Europe. Finally implement research on simplification of mixtures to identify the active compounds in Neuroaid mixture."

On receiving the BioSpectrum Asia Pacific Emerging Company of the Year 2010 Award, Mr David Picard says, "We are very happy about our progress towards bringing therapeutics to meet the needs of the sufferers and we are proud of these efforts being recognized by BioSpectrum. Thank you very much for your encouragement and support," he concludes.